Abstract
The kinetics of the postantibiotic effect (PAE) during one dosing interval of tobramycin against Staphylococcus aureus and Pseudomonas aeruginosa was investigated. We determined the PAE at different time points during this dosing interval of 12 h in an in vitro pharmacokinetic model simulating human pharmacokinetics in which the half-life of tobramycin was adjusted to 2.4 +/- 0.2 h. Using an enzymatic method to inactivate tobramycin, we determined PAEs in samples extracted from the model at 1, 5, 8, and 12 h, corresponding with tobramycin concentrations of 20, 5, 2, and 1 times the MIC for the test organism. The PAE decreased significantly from 2.5 h at 1 h to 0 h at 12 h. No change in MIC was observed for the strains during the experiments. We conclude that the PAE decreases with decreasing tobramycin concentrations during a 12-h dosing interval and completely disappears after the concentration has reached the MIC for the test organism. On the basis of these observations, the emphasis that is placed on the PAE in discussions about the optimal dosing interval in aminoglycoside therapy is questionable.
Full Text
The Full Text of this article is available as a PDF (181.5 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Craig W. A., Ebert S. C. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis Suppl. 1990;74:63–70. [PubMed] [Google Scholar]
- Craig W. A. Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man. J Antimicrob Chemother. 1993 May;31 (Suppl 500):149–158. doi: 10.1093/jac/31.suppl_d.149. [DOI] [PubMed] [Google Scholar]
- Craig W. A., Redington J., Ebert S. C. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother. 1991 May;27 (Suppl 100):29–40. doi: 10.1093/jac/27.suppl_c.29. [DOI] [PubMed] [Google Scholar]
- Gilbert D. N. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother. 1991 Mar;35(3):399–405. doi: 10.1128/aac.35.3.399. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Isaksson B., Nilsson L., Maller R., Sörén L. Postantibiotic effect of aminoglycosides on gram-negative bacteria evaluated by a new method. J Antimicrob Chemother. 1988 Jul;22(1):23–33. doi: 10.1093/jac/22.1.23. [DOI] [PubMed] [Google Scholar]
- Kapusnik J. E., Hackbarth C. J., Chambers H. F., Carpenter T., Sande M. A. Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia. J Infect Dis. 1988 Jul;158(1):7–12. doi: 10.1093/infdis/158.1.7. [DOI] [PubMed] [Google Scholar]
- Karlowsky J. A., Zhanel G. G., Davidson R. J., Hoban D. J. Once-daily aminoglycoside dosing assessed by MIC reversion time with Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1994 May;38(5):1165–1168. doi: 10.1128/aac.38.5.1165. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Karlowsky J. A., Zhanel G. G., Davidson R. J., Hoban D. J. Postantibiotic effect in Pseudomonas aeruginosa following single and multiple aminoglycoside exposures in vitro. J Antimicrob Chemother. 1994 May;33(5):937–947. doi: 10.1093/jac/33.5.937. [DOI] [PubMed] [Google Scholar]
- Karlowsky J. A., Zhanel G. G., Davidson R. J., Zieroth S. R., Hoban D. J. In vitro postantibiotic effects following multiple exposures of cefotaxime, ciprofloxacin, and gentamicin against Escherichia coli in pooled human cerebrospinal fluid and Mueller-Hinton broth. Antimicrob Agents Chemother. 1993 May;37(5):1154–1157. doi: 10.1128/aac.37.5.1154. [DOI] [PMC free article] [PubMed] [Google Scholar]
- McGrath B. J., Marchbanks C. R., Gilbert D., Dudley M. N. In vitro postantibiotic effect following repeated exposure to imipenem, temafloxacin, and tobramycin. Antimicrob Agents Chemother. 1993 Aug;37(8):1723–1725. doi: 10.1128/aac.37.8.1723. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mouton J. W., den Hollander J. G. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 1994 May;38(5):931–936. doi: 10.1128/aac.38.5.931. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nicolau D. P., Freeman C. D., Belliveau P. P., Nightingale C. H., Ross J. W., Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995 Mar;39(3):650–655. doi: 10.1128/AAC.39.3.650. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Odenholt-Tornqvist I., Löwdin E., Cars O. Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin. Antimicrob Agents Chemother. 1992 Sep;36(9):1852–1858. doi: 10.1128/aac.36.9.1852. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vogelman B., Gudmundsson S., Turnidge J., Leggett J., Craig W. A. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis. 1988 Feb;157(2):287–298. doi: 10.1093/infdis/157.2.287. [DOI] [PubMed] [Google Scholar]
- den Hollander J. G., Mouton J. W., Bakker-Woudenberg I. A., Vleggaar F. P., van Goor M. P., Verbrugh H. A. Enzymatic method for inactivation of aminoglycosides during measurement of postantibiotic effect. Antimicrob Agents Chemother. 1996 Feb;40(2):488–490. doi: 10.1128/aac.40.2.488. [DOI] [PMC free article] [PubMed] [Google Scholar]
- ter Braak E. W., de Vries P. J., Bouter K. P., van der Vegt S. G., Dorrestein G. C., Nortier J. W., van Dijk A., Verkooyen R. P., Verbrugh H. A. Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med. 1990 Jul;89(1):58–66. doi: 10.1016/0002-9343(90)90099-y. [DOI] [PubMed] [Google Scholar]